EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Pharmacokinetic and Bioequivalence Evaluation of Two Sitagliptin Tablets With Different Salts in Healthy Subjects

Usok Hyun, Seongnam Chu, Sungyun Kim, Jung-Ki Hong, Taeyoung Kim, In-Soo Yoon, Jung-Jin Kim, Hyun-Jong Cho

Clinical Pharmacology in Drug Development · 2025-10 · 14 (10) · 781-786

DOI: 10.1002/cpdd.1573 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 11.07.2025. Verfasst von Usok Hyun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of the current study was to evaluate the rate and extent of absorption of a test formulation (sitagliptin hydrochloride) and a reference formulation (sitagliptin phosphate). An open‐label, randomized, single‐dose, single‐center, 2‐sequence, 2‐period, and cross‐over phase 1 study was implemented to assess the pharmacokinetic bioequivalence of the test and reference formulations containing a single dose of sitagliptin 100 mg in 32 healthy volunteers under fasting conditions. The differences between the test and reference formulations in terms of the area under the curve from dosing to the time of the last measured concentration (AUC last ) and the maximum concentration (C max ) were found to be not significant. The 90% confidence intervals of sitagliptin Ln‐transformed AUC last and C max were within the pharmacokinetic bioequivalence acceptance range of 80%‐125%. The test formulation with sitagliptin hydrochloride was bioequivalent to the reference formulation with sitagliptin phosphate in healthy male volunteers under fasting conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsHumansTherapeutic EquivalencyMaleCross-Over StudiesAdultTabletsHealthy VolunteersYoung AdultArea Under CurveFastingSaltsMiddle AgedAdministration, Oral

Stichwörter der Autor:innen

bioequivalenceclinical pharmacokineticspreclinical studysitagliptin hydrochloridesitagliptin phosphate

Substanzen

Sitagliptin PhosphateTabletsDipeptidyl-Peptidase IV InhibitorsSalts

Autor:innen und Institutionen

  • Department of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea.
  • Daehwa Pharmaceutical Co., Ltd, Seoul, Republic of Korea.
  • Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
  • Department of Pharmaceutical Engineering, College of Food & Pharmaceutical Engineering, Mokpo National University, Muan, Jeonnam, Republic of Korea.

Zitieren

APA

Hyun, U., Chu, S., Kim, S., Hong, J. K., Kim, T., Yoon, I. S., Kim, J. J., & Cho, H. J. (2025). Pharmacokinetic and Bioequivalence Evaluation of Two Sitagliptin Tablets With Different Salts in Healthy Subjects. Clinical Pharmacology in Drug Development, 14(10), 781-786. https://doi.org/10.1002/cpdd.1573

Vancouver

Hyun U, Chu S, Kim S, Hong JK, Kim T, Yoon IS, et al. Pharmacokinetic and Bioequivalence Evaluation of Two Sitagliptin Tablets With Different Salts in Healthy Subjects. Clinical Pharmacology in Drug Development. 2025;14(10):781-786. doi:10.1002/cpdd.1573

BibTeX
@article{Hyun2025,
  author = {Hyun, Usok and Chu, Seongnam and Kim, Sungyun and Hong, Jung-Ki and Kim, Taeyoung and Yoon, In-Soo and Kim, Jung-Jin and Cho, Hyun-Jong},
  title = {Pharmacokinetic and Bioequivalence Evaluation of Two Sitagliptin Tablets With Different Salts in Healthy Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  volume = {14},
  number = {10},
  pages = {781--786},
  doi = {10.1002/cpdd.1573}
}
Kostenlos starten →